Measures of glucose homeostasis during and after duodenal exclusion using a duodenal-jejunal bypass liner in a normoglycemic, nonobese canine model.


Journal

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
ISSN: 1878-7533
Titre abrégé: Surg Obes Relat Dis
Pays: United States
ID NLM: 101233161

Informations de publication

Date de publication:
06 2022
Historique:
received: 09 06 2021
revised: 31 01 2022
accepted: 11 02 2022
pubmed: 2 4 2022
medline: 9 6 2022
entrez: 1 4 2022
Statut: ppublish

Résumé

Discovering the role duodenal exclusion plays in weight loss and resolution of type 2 diabetes (T2D) may help refine the surgical and nonsurgical treatment of obesity and T2D. To assess changes in glucose homeostasis due to duodenal exclusion using a duodenal-jejunal bypass liner (DJBL) in a nonobese canine model. Academic laboratory setting. An intravenous glucose tolerance test (IVGTT), and a mixed-meal tolerance test (MMTT) at baseline, 1, and 6 weeks post DJBL implantation (I1 and I6, respectively), and 1 and 6 weeks post DJBL removal (R1 and R6, respectively) were done in canines (n = 7) fed a normal chow diet. Placement of the DJBL induced weight loss that was maintained until 4 weeks post removal (R4), despite normal food intake. Total bile acids (TBA) and glucagon-like peptide-1 (GLP-1) during the MMTT were significantly increased at I1 and were associated with increased lactate and free fatty acids. Hypoglycemia counter-regulation was blunted during the IVGTT at I1 and I6, returning to baseline at R1. While there were no changes to insulin sensitivity during the experiment, glucose tolerance was significantly increased following the removal of the DJBL at R1. These data show that in a normoglycemic, nonobese canine model, duodenal exclusion induces energy intake-independent weight loss and negative metabolic effects that are reversed following re-exposure of the small intestine to nutrients.

Sections du résumé

BACKGROUND
Discovering the role duodenal exclusion plays in weight loss and resolution of type 2 diabetes (T2D) may help refine the surgical and nonsurgical treatment of obesity and T2D.
OBJECTIVES
To assess changes in glucose homeostasis due to duodenal exclusion using a duodenal-jejunal bypass liner (DJBL) in a nonobese canine model.
SETTING
Academic laboratory setting.
METHODS
An intravenous glucose tolerance test (IVGTT), and a mixed-meal tolerance test (MMTT) at baseline, 1, and 6 weeks post DJBL implantation (I1 and I6, respectively), and 1 and 6 weeks post DJBL removal (R1 and R6, respectively) were done in canines (n = 7) fed a normal chow diet.
RESULTS
Placement of the DJBL induced weight loss that was maintained until 4 weeks post removal (R4), despite normal food intake. Total bile acids (TBA) and glucagon-like peptide-1 (GLP-1) during the MMTT were significantly increased at I1 and were associated with increased lactate and free fatty acids. Hypoglycemia counter-regulation was blunted during the IVGTT at I1 and I6, returning to baseline at R1. While there were no changes to insulin sensitivity during the experiment, glucose tolerance was significantly increased following the removal of the DJBL at R1.
CONCLUSION
These data show that in a normoglycemic, nonobese canine model, duodenal exclusion induces energy intake-independent weight loss and negative metabolic effects that are reversed following re-exposure of the small intestine to nutrients.

Identifiants

pubmed: 35361540
pii: S1550-7289(22)00082-X
doi: 10.1016/j.soard.2022.02.012
pmc: PMC10013877
mid: NIHMS1793498
pii:
doi:

Substances chimiques

Blood Glucose 0
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

694-702

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK027619
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK029867
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

Références

Diabetes. 2013 Dec;62(12):4239-46
pubmed: 23939392
Diabetes Obes Metab. 2017 Feb;19(2):189-199
pubmed: 27696668
Cell Signal. 2000 Oct;12(9-10):583-94
pubmed: 11080610
J Appl Physiol (1985). 2001 Jan;90(1):155-63
pubmed: 11133906
Ann Surg. 2010 Feb;251(2):236-43
pubmed: 19858703
Cell Metab. 2009 Sep;10(3):167-77
pubmed: 19723493
Surg Endosc. 2017 Jul;31(7):2881-2891
pubmed: 27804045
J Clin Invest. 2006 Jul;116(7):1793-801
pubmed: 16823477
Mol Metab. 2019 Dec;30:72-130
pubmed: 31767182
J Pediatr Surg. 2018 Jun;53(6):1142-1147
pubmed: 29588076
Diabetes Obes Metab. 2016 Mar;18(3):300-5
pubmed: 26537317
Hepatology. 2012 Oct;56(4):1300-10
pubmed: 22531947
Gastroenterology. 2016 Feb;150(2):454-64.e9
pubmed: 26481855
J Pediatr Surg. 2010 May;45(5):987-95
pubmed: 20438940
Am J Physiol Endocrinol Metab. 2015 Mar 15;308(6):E535-44
pubmed: 25628424
J Mol Endocrinol. 2005 Aug;35(1):27-38
pubmed: 16087719
Obes Surg. 2018 Nov;28(11):3405-3414
pubmed: 29790128
Diabetes Technol Ther. 2009 Nov;11(11):725-32
pubmed: 19905889
Biochim Biophys Acta. 1976 Feb 23;424(2):264-73
pubmed: 1252491
J Endocrinol. 2016 Oct;231(1):11-22
pubmed: 27474690
Diabetes. 1997 Aug;46(8):1328-35
pubmed: 9231658
Obes Surg. 2012 Jul;22(7):1084-96
pubmed: 22359255
Am J Physiol. 1984 Sep;247(3 Pt 1):E362-9
pubmed: 6383070
Obes Surg. 2017 Dec;27(12):3306-3313
pubmed: 29018990
Obes Surg. 2015 Sep;25(9):1618-25
pubmed: 25691349
Obes Surg. 2013 Sep;23(9):1354-60
pubmed: 23526068
Surg Endosc. 2020 Jan;34(1):209-215
pubmed: 30877567
Obes Surg. 2018 Jul;28(7):1980-1989
pubmed: 29450844
N Engl J Med. 2007 Aug 23;357(8):741-52
pubmed: 17715408
Obes Surg. 2014 Feb;24(2):337-41
pubmed: 24357127
Diabetes. 2000 Nov;49(11):1897-903
pubmed: 11078457
Metabolism. 2003 Jul;52(7):900-7
pubmed: 12870168
Biochem J. 1973 Aug;134(4):1067-81
pubmed: 4762752
Diabetes. 2003 Nov;52(11):2748-58
pubmed: 14578293
JAMA. 2004 Oct 13;292(14):1724-37
pubmed: 15479938
Diabetes. 2015 Jun;64(6):1941-50
pubmed: 25576062
Diabetes. 2005 Jun;54(6):1640-8
pubmed: 15919784
Am J Physiol Gastrointest Liver Physiol. 2009 Nov;297(5):G950-7
pubmed: 20501442

Auteurs

Rebecca L Paszkiewicz (RL)

Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: rpaszkiewicz@mednet.ucla.edu.

Miguel A Burch (MA)

Minimally Invasive and GI Surgery, Cedars-Sinai Medical Center, Los Angeles, California.

Isaac Asare Bediako (I)

Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.

Hasmik Mkrtchyan (H)

Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.

Francesca Piccinini (F)

Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.

Marilyn Ader (M)

Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.

Catherine Bresee (C)

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.

Richard N Bergman (RN)

Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH